

Name of the Issue: Mankind Pharma Limited			
1	Type of Issue	Initial Public Offer	
2	Issue Size (Rs. Mn)	43263.55*	
	*Source: Prospectus dated April 28, 2023		
3	Grade of issue along with name of the rating agency		
	Name	NA	
	Grade	NA	
4	Subscription Level (Number of times)	15.4631*	
	* excluding Anchor Investor Portion and after removing multiple and duplicate bids		
	Source: Minutes for basis of allotment dated May 03, 2023		
5	QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges		
	Particulars	%	
	(i) On Allotment **	5.28%	
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2023)	4.18%	
	(iii) at the end of 1st FY (March 31, 2024)	21.01%	
	(iv) at the end of 2nd FY (March 31, 2025)	24.40%	
	(v) at the end of 3rd FY (March 31, 2026) *	Not Available	
	**Basis of Allotment (excluding pre-issue QIB holding)		
	* QIB Holding not disclosed as reporting for relevant period has not been completed.		
6	Financials of the issuer		Rs. In lacs
	Parameters	1st FY (March 31,2024)	2nd FY (March 31,2025)
			3rd FY (March 31,2026)*
	Income from operations	10,33,477.46	12,20,744.00
	Net Profit/(Loss) for the period	1,94,177.17	2,06,059
	Paid-up equity share capital	4,005.88	4,126
	Reserves excluding revaluation reserves	9,32,302.93	1,42,913
	* Financials not available as reporting for the relevant years has not been completed.		
7	Trading Status		
	The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")		
	The equity shares have not been suspended or delisted.		
	Particulars	Status	
	(i) at the end of 1st FY (March 31, 2024)	Frequently Traded	
	(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded	
	(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	
	* Trading status not disclosed as the relevant fiscal years have not been completed.		

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	No change	NA
(ii) at the end of 2nd FY (March 31, 2025)	No change	NA
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	1080.00
Listing Date	May 09, 2023

Price parameters	At close of listing day- May 09, 2023	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March,2024)		
				Closing price	High	Low
Market Price	1,430.00	1,486.2	1,803.5	2,300.8	2,336.4	1,322.7
Nifty 50*	18,265.95	18,726.4	19,597.3	22,326.9	22,493.6	17,398.1

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2025)			As at the end of the 3rd FY after the listing of the issue (31st March,2026) ⁽¹⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price	2,424.75	3,054.80	1,901.05	Not Available	Not Available	Not Available
Nifty 50*	23,519.35	26,277.35	21,281.45	Not Available	Not Available	Not Available

* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2024)	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)**
EPS (Diluted)	Company				
	<i>Consolidated</i>	1	35.78	47.68	49.20
	Peer Group:				
	<i>Sun Pharmaceuticals Industries Limited</i>	1	13.60	39.9	17.80
	<i>Cipla Limited</i>	2	31.17	51.01	63.82
	<i>Zydus Lifesciences Limited</i>	1	43.83	38.14	57.39
	<i>Torrent Pharmaceutical Limited</i>	5	22.97	48.94	55.79
	<i>Alkem Laboratories</i>	2	137.63	150.19	181.11
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	49.82	34.85	41.16
	<i>Eris Lifesciences Limited</i>	1	29.88	28.79	5.68
	<i>Ipca Laboratories Limited</i>	2	34.85	21.57	25.65
	<i>Abbott India Limited</i>	10	375.86	565.28	665.62
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	100.04	34.83	—
	<i>Dabur India Limited</i>	1	9.81	10.38	9.95
	<i>Procter & Gamble Health Limited</i>	10	116.00	Not Available	110.97
	<i>Zydus Wellness Limited</i>	10	48.54	41.94	4.81
	Industry Avg		78.00	88.82	103.31
P/E	Company				
	<i>Consolidated</i>	1	30.18	48.25	49.00
	Peer Group:				
	<i>Sun Pharmaceuticals Industries Limited</i>	1	71.54	40.62	97.41
	<i>Cipla Limited</i>	2	28.18	29.35	23.09
	<i>Zydus Lifesciences Limited</i>	1	10.95	26.41	17.09
	<i>Torrent Pharmaceutical Limited</i>	5	66.25	53.14	58.14
	<i>Alkem Laboratories</i>	2	23.03	32.90	26.82
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	39.48	47.36	41.83
	<i>Eris Lifesciences Limited</i>	1	19.1	29.29	63.57
	<i>Ipca Laboratories Limited</i>	2	22.38	57.37	41.28
	<i>Abbott India Limited</i>	10	56.19	47.98	47.34
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	57.03	55.89	—
	<i>Dabur India Limited</i>	1	54.55	50.40	47.77
	<i>Procter & Gamble Health Limited</i>	10	42.27	Not Available	120.80
	<i>Zydus Wellness Limited</i>	10	31.11	35.18	404.47
	Industry Avg		40.16	42.16	82.46

RoNW	Company				
	Consolidated	1	23.29%	20.74%	13.70%
	Peer Group:				
	<i>Sun Pharmaceuticals Industries Limited</i>	1	6.82%	15.04%	13.09%
	<i>Cipla Limited</i>	2	12.08%	15.55%	16.84%
	<i>Zydus Lifesciences Limited</i>	1	26.40%	19.46%	27.25%
	<i>Torrent Pharmaceutical Limited</i>	5	13.06%	24.15%	24.87%
	<i>Alkem Laboratories</i>	2	19.05%	17.57%	18.48%
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	18.06%	18.90%	19.35%
	<i>Eris Lifesciences Limited</i>	1	21.28%	15.35%	3.07%
	<i>Ipca Laboratories Limited</i>	2	16.10%	8.36%	8.50%
	<i>Abbott India Limited</i>	10	28.32%	32.48%	33.41%
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	63.64%	33.19%	—
	<i>Dabur India Limited</i>	1	20.75%	18.36%	16.11%
	<i>Procter & Gamble Health Limited</i>	10	31.23%	Not Available	34.30%
	<i>Zydus Wellness Limited</i>	10	6.38%	4.98%	0.76%
	Industry Avg		21.78%	18.62%	18%
NAV per share	Company				
	Consolidated	10	31.76	233.73	355.34
	Peer Group:				
	<i>Sun Pharmaceuticals Industries Limited</i>	1	200.10	265.35	227.98
	<i>Cipla Limited</i>	2	258.32	330.78	193.71
	<i>Zydus Lifesciences Limited</i>	1	166.05	197.07	105.95
	<i>Torrent Pharmaceutical Limited</i>	5	175.89	202.58	22.40
	<i>Alkem Laboratories</i>	2	722.44	862.46	1,002.33
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	240.83	188.37	217.46
	<i>Eris Lifesciences Limited</i>	1	140.39	190.12	184.64
	<i>Ipca Laboratories Limited</i>	2	216.47	249.59	220.50
	<i>Abbott India Limited</i>	10	1,327.00	1,740.71	199.21
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	157.19	104.93	—
	<i>Dabur India Limited</i>	1	47.41	55.68	6.09
	<i>Procter & Gamble Health Limited</i>	10	371.39	Not Available	21.92
	<i>Zydus Wellness Limited</i>	10	761.26	841.95	6,343.71
	Industry Avg		368.06	435.80	728.76

Notes

* Sourced from Prospectus dated April 28, 2023.

**Not available as the relevant fiscal years have not been completed / information not disclosed

14 Any other material information

Particulars	Date	Remarks
Not Applicable		

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com